KROS Stock Analysis: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$11.26
0.38 (3.49%)
▲
5d:
+8.17%
30d:
+6.73%
90d:
-3.68%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $11.26, which is considered extended relative to its 30-day fair value range of $10.21 to $11.11.
Technical Outlook: Technically, KROS is in a strong downtrend. The price is approaching resistance at $11.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $21.83 (+93.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KROS is in a strong downtrend. The price is approaching resistance at $11.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $21.83 (+93.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.21 -
$11.11
Company Quality Score
52/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
54.2%
Protect Your Profits
Holding KROS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 93.9% below Wall St target ($21.83)
Trading Range Analysis
30-Day Trading Range
$10.21 -
$11.11
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.90
(25.8%)
Support & Resistance Levels
Support Level
$10.30
Resistance Level
$11.47
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.01
Wall Street Target
$21.83
(+93.9%)
Revenue Growth (YoY)
-99.8%
Profit Margin
-256.6%
Share & Embed Analysis
Last updated: July 02, 2026 10:43 PM ET
Data refreshes hourly during market hours. Next update: 11:43 PM
Data refreshes hourly during market hours. Next update: 11:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jean Jacques Bienaime
BUY
1000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
